Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 100

1.

Phase III randomized trial of bisphosphonates as adjuvant therapy in breast cancer: S0307.

Gralow JR, Barlow WE, Paterson AHG, Miao JL, Lew DL, Stopeck AT, Hayes DF, Hershman DL, Schubert MM, Clemons M, Van Poznak CH, Dees EC, Ingle JN, Falkson CI, Elias AD, Messino MJ, Margolis JH, Dakhil SR, Chew HK, Dammann KZ, Abrams JS, Livingston RB, Hortobagyi GN.

J Natl Cancer Inst. 2019 Oct 31. pii: djz215. doi: 10.1093/jnci/djz215. [Epub ahead of print]

PMID:
31693129
2.

A Phase II Study of Irinotecan and Etoposide as Treatment for Refractory Metastatic Breast Cancer.

Segar JM, Reed D, Stopeck A, Livingston RB, Chalasani P.

Oncologist. 2019 Aug 5. pii: theoncologist.2019-0516. doi: 10.1634/theoncologist.2019-0516. [Epub ahead of print]

PMID:
31383812
3.

Cost-effectiveness of denosumab for the prevention of skeletal-related events in patients with solid tumors and bone metastases in the United States.

Stopeck A, Brufsky A, Kennedy L, Bhatta S, Bhowmik D, Buchanan J, Despiegel N, Hechmati G.

J Med Econ. 2019 Aug 26:1-11. doi: 10.1080/13696998.2019.1651122. [Epub ahead of print]

PMID:
31364885
4.

Phase 1b Study of Trebananib Plus Paclitaxel and Trastuzumab in Patients With HER2-Positive Locally Recurrent or Metastatic Breast Cancer.

Kaufman PA, Wildiers H, Freyer G, Kemeny M, Gonçalves A, Jerusalem G, Stopeck A, Vrindavanam N, Dalenc F, Nanayakkara N, Wu B, Pickett CA.

Clin Breast Cancer. 2019 Feb;19(1):47-57. doi: 10.1016/j.clbc.2018.09.012. Epub 2018 Oct 9.

PMID:
30420181
5.

Reproducible automated breast density measure with no ionizing radiation using fat-water decomposition MRI.

Ding J, Stopeck AT, Gao Y, Marron MT, Wertheim BC, Altbach MI, Galons JP, Roe DJ, Wang F, Maskarinec G, Thomson CA, Thompson PA, Huang C.

J Magn Reson Imaging. 2018 Oct;48(4):971-981. doi: 10.1002/jmri.26041. Epub 2018 Apr 6.

6.

A randomized, placebo-controlled trial of diindolylmethane for breast cancer biomarker modulation in patients taking tamoxifen.

Thomson CA, Chow HHS, Wertheim BC, Roe DJ, Stopeck A, Maskarinec G, Altbach M, Chalasani P, Huang C, Strom MB, Galons JP, Thompson PA.

Breast Cancer Res Treat. 2017 Aug;165(1):97-107. doi: 10.1007/s10549-017-4292-7. Epub 2017 May 30.

7.

Osteoclast inhibition in postmenopausal breast cancer: Is the evidence too strong to ignore?

Stopeck AT.

Cancer. 2017 Jul 1;123(13):2392-2394. doi: 10.1002/cncr.30678. Epub 2017 May 2. No abstract available.

8.

Response to letter to the Editors-Safety of long-term denosumab therapy.

Stopeck AT, Warner DJ.

Support Care Cancer. 2017 Feb;25(2):353-355. doi: 10.1007/s00520-016-3492-8. Epub 2016 Nov 24. No abstract available.

9.

Changes in Bone Turnover Marker Levels and Clinical Outcomes in Patients with Advanced Cancer and Bone Metastases Treated with Bone Antiresorptive Agents.

Lipton A, Smith MR, Fizazi K, Stopeck AT, Henry D, Brown JE, Shore ND, Saad F, Spencer A, Zhu L, Warner DJ.

Clin Cancer Res. 2016 Dec 1;22(23):5713-5721. Epub 2016 May 2.

10.

Phase II study of metformin for reduction of obesity-associated breast cancer risk: a randomized controlled trial protocol.

Martinez JA, Chalasani P, Thomson CA, Roe D, Altbach M, Galons JP, Stopeck A, Thompson PA, Villa-Guillen DE, Chow HH.

BMC Cancer. 2016 Jul 19;16:500. doi: 10.1186/s12885-016-2551-3.

11.

Extending Aromatase-Inhibitor Adjuvant Therapy to 10 Years.

Goss PE, Ingle JN, Pritchard KI, Robert NJ, Muss H, Gralow J, Gelmon K, Whelan T, Strasser-Weippl K, Rubin S, Sturtz K, Wolff AC, Winer E, Hudis C, Stopeck A, Beck JT, Kaur JS, Whelan K, Tu D, Parulekar WR.

N Engl J Med. 2016 Jul 21;375(3):209-19. doi: 10.1056/NEJMoa1604700. Epub 2016 Jun 5.

12.

Circulating Carbonic Anhydrase IX and Antiangiogenic Therapy in Breast Cancer.

Brown-Glaberman U, Marron M, Chalasani P, Livingston R, Iannone M, Specht J, Stopeck AT.

Dis Markers. 2016;2016:9810383. doi: 10.1155/2016/9810383. Epub 2016 Jan 28.

13.

Pathophysiology of tumour-induced microangiopathic haemolytic anaemia.

Chalasani P, Segar JM, Marron M, Stopeck A.

BMJ Case Rep. 2016 Jan 7;2016. pii: bcr2015213521. doi: 10.1136/bcr-2015-213521.

14.

A maximum-likelihood method to estimate a single ADC value of lesions using diffusion MRI.

Jha AK, Rodríguez JJ, Stopeck AT.

Magn Reson Med. 2016 Dec;76(6):1919-1931. doi: 10.1002/mrm.26072. Epub 2016 Jan 7.

15.

Effect of denosumab versus zoledronic acid in preventing skeletal-related events in patients with bone metastases by baseline characteristics.

Lipton A, Fizazi K, Stopeck AT, Henry DH, Smith MR, Shore N, Martin M, Vadhan-Raj S, Brown JE, Richardson GE, Saad F, Yardley DA, Zhou K, Balakumaran A, Braun A.

Eur J Cancer. 2016 Jan;53:75-83. doi: 10.1016/j.ejca.2015.09.011. Epub 2015 Dec 13.

16.

Erratum to: Safety of long-term denosumab therapy: results from the open label extension phase of two phase 3 studies in patients with metastatic breast and prostate cancer.

Stopeck AT, Fizazi K, Body JJ, Brown JE, Carducci M, Diel I, Fujiwara Y, Martín M, Paterson A, Tonkin K, Shore N, Sieber P, Kueppers F, Karsh L, Yardley D, Wang H, Maniar T, Arellano J, Braun A.

Support Care Cancer. 2016 Jan;24(1):457-458. doi: 10.1007/s00520-015-2985-1. No abstract available.

PMID:
26482379
17.

Safety of long-term denosumab therapy: results from the open label extension phase of two phase 3 studies in patients with metastatic breast and prostate cancer.

Stopeck AT, Fizazi K, Body JJ, Brown JE, Carducci M, Diel I, Fujiwara Y, Martín M, Paterson A, Tonkin K, Shore N, Sieber P, Kueppers F, Karsh L, Yardley D, Wang H, Maniar T, Arellano J, Braun A.

Support Care Cancer. 2016 Jan;24(1):447-455. doi: 10.1007/s00520-015-2904-5. Epub 2015 Sep 3. Erratum in: Support Care Cancer. 2015 Oct 19;:.

18.

Pain and analgesic use associated with skeletal-related events in patients with advanced cancer and bone metastases.

von Moos R, Body JJ, Egerdie B, Stopeck A, Brown J, Fallowfield L, Patrick DL, Cleeland C, Damyanov D, Palazzo FS, Marx G, Zhou Y, Braun A, Balakumaran A, Qian Y.

Support Care Cancer. 2016 Mar;24(3):1327-37. doi: 10.1007/s00520-015-2908-1. Epub 2015 Sep 2.

19.

Diffusion MRI with Semi-Automated Segmentation Can Serve as a Restricted Predictive Biomarker of the Therapeutic Response of Liver Metastasis.

Stephen RM, Jha AK, Roe DJ, Trouard TP, Galons JP, Kupinski MA, Frey G, Cui H, Squire S, Pagel MD, Rodriguez JJ, Gillies RJ, Stopeck AT.

Magn Reson Imaging. 2015 Dec;33(10):1267-1273. doi: 10.1016/j.mri.2015.08.006. Epub 2015 Aug 15.

20.

Hypocalcaemia in patients with metastatic bone disease treated with denosumab.

Body JJ, Bone HG, de Boer RH, Stopeck A, Van Poznak C, Damião R, Fizazi K, Henry DH, Ibrahim T, Lipton A, Saad F, Shore N, Takano T, Shaywitz AJ, Wang H, Bracco OL, Braun A, Kostenuik PJ.

Eur J Cancer. 2015 Sep;51(13):1812-21. doi: 10.1016/j.ejca.2015.05.016. Epub 2015 Jun 17.

21.

Intravenous thiotepa for treatment of breast cancer-related leptomeningeal carcinomatosis: case series.

Chahal J, Stopeck A, Clarke K, Livingston RB, Chalasani P.

Neurol Sci. 2015 Sep;36(9):1691-3. doi: 10.1007/s10072-015-2259-1. Epub 2015 May 20.

PMID:
25990104
22.

The role of denosumab in the prevention of hypercalcaemia of malignancy in cancer patients with metastatic bone disease.

Diel IJ, Body JJ, Stopeck AT, Vadhan-Raj S, Spencer A, Steger G, von Moos R, Goldwasser F, Feng A, Braun A.

Eur J Cancer. 2015 Jul;51(11):1467-75. doi: 10.1016/j.ejca.2015.04.017. Epub 2015 May 11.

PMID:
25976743
23.

EMERGE: A Randomized Phase II Study of the Antibody-Drug Conjugate Glembatumumab Vedotin in Advanced Glycoprotein NMB-Expressing Breast Cancer.

Yardley DA, Weaver R, Melisko ME, Saleh MN, Arena FP, Forero A, Cigler T, Stopeck A, Citrin D, Oliff I, Bechhold R, Loutfi R, Garcia AA, Cruickshank S, Crowley E, Green J, Hawthorne T, Yellin MJ, Davis TA, Vahdat LT.

J Clin Oncol. 2015 May 10;33(14):1609-19. doi: 10.1200/JCO.2014.56.2959. Epub 2015 Apr 6.

PMID:
25847941
24.

A phase I clinical trial of bavituximab and paclitaxel in patients with HER2 negative metastatic breast cancer.

Chalasani P, Marron M, Roe D, Clarke K, Iannone M, Livingston RB, Shan JS, Stopeck AT.

Cancer Med. 2015 Jul;4(7):1051-9. doi: 10.1002/cam4.447. Epub 2015 Mar 31.

25.

Automated breast segmentation of fat and water MR images using dynamic programming.

Rosado-Toro JA, Barr T, Galons JP, Marron MT, Stopeck A, Thomson C, Thompson P, Carroll D, Wolf E, Altbach MI, Rodríguez JJ.

Acad Radiol. 2015 Feb;22(2):139-48. doi: 10.1016/j.acra.2014.09.015.

26.

A pilot study of estradiol followed by exemestane for reversing endocrine resistance in postmenopausal women with hormone receptor-positive metastatic breast cancer.

Chalasani P, Stopeck A, Clarke K, Livingston R.

Oncologist. 2014 Nov;19(11):1127-8. doi: 10.1634/theoncologist.2014-0306. Epub 2014 Sep 26.

27.

Assessment of carbonic anhydrase IX expression and extracellular pH in B-cell lymphoma cell line models.

Chen LQ, Howison CM, Spier C, Stopeck AT, Malm SW, Pagel MD, Baker AF.

Leuk Lymphoma. 2015 May;56(5):1432-9. doi: 10.3109/10428194.2014.933218. Epub 2014 Nov 10.

28.

Isolation of viable cancer cells in antibody-functionalized microfluidic devices.

Zheng X, Jiang L, Schroeder J, Stopeck A, Zohar Y.

Biomicrofluidics. 2014 Apr 30;8(2):024119. doi: 10.1063/1.4873956. eCollection 2014 Mar.

29.

Utilities associated with subcutaneous injections and intravenous infusions for treatment of patients with bone metastases.

Matza LS, Cong Z, Chung K, Stopeck A, Tonkin K, Brown J, Braun A, Van Brunt K, McDaniel K.

Patient Prefer Adherence. 2013 Aug 29;7:855-65. doi: 10.2147/PPA.S44947. eCollection 2013.

30.

Pain and health-related quality of life in patients with advanced solid tumours and bone metastases: integrated results from three randomized, double-blind studies of denosumab and zoledronic acid.

von Moos R, Body JJ, Egerdie B, Stopeck A, Brown JE, Damyanov D, Fallowfield LJ, Marx G, Cleeland CS, Patrick DL, Palazzo FG, Qian Y, Braun A, Chung K.

Support Care Cancer. 2013 Dec;21(12):3497-507. doi: 10.1007/s00520-013-1932-2. Epub 2013 Aug 22.

PMID:
23975226
31.

Impact of denosumab on bone mass in cancer patients.

Brown-Glaberman U, Stopeck AT.

Clin Pharmacol. 2013 Jul 4;5:117-29. doi: 10.2147/CPAA.S30330. Print 2013.

32.

Reply to Araki et al.

Lipton A, Fizazi K, Stopeck AT, Henry DH, Braun AH.

Eur J Cancer. 2013 Jun;49(9):2266-8. doi: 10.1016/j.ejca.2013.02.037. Epub 2013 Apr 8. No abstract available.

PMID:
23578571
33.

Authors' response to letter to the editor.

Stopeck A, Henry D, Dansey R, Qian Y, Cong Z, Arellano J.

J Med Econ. 2013;16(2):262-3. No abstract available.

PMID:
23424726
34.

Superiority of denosumab to zoledronic acid for prevention of skeletal-related events: a combined analysis of 3 pivotal, randomised, phase 3 trials.

Lipton A, Fizazi K, Stopeck AT, Henry DH, Brown JE, Yardley DA, Richardson GE, Siena S, Maroto P, Clemens M, Bilynskyy B, Charu V, Beuzeboc P, Rader M, Viniegra M, Saad F, Ke C, Braun A, Jun S.

Eur J Cancer. 2012 Nov;48(16):3082-92. doi: 10.1016/j.ejca.2012.08.002. Epub 2012 Sep 10.

PMID:
22975218
35.

Pain outcomes in patients with advanced breast cancer and bone metastases: results from a randomized, double-blind study of denosumab and zoledronic acid.

Cleeland CS, Body JJ, Stopeck A, von Moos R, Fallowfield L, Mathias SD, Patrick DL, Clemons M, Tonkin K, Masuda N, Lipton A, de Boer R, Salvagni S, Oliveira CT, Qian Y, Jiang Q, Dansey R, Braun A, Chung K.

Cancer. 2013 Feb 15;119(4):832-8. doi: 10.1002/cncr.27789. Epub 2012 Sep 5.

36.

Bone-related complications and quality of life in advanced breast cancer: results from a randomized phase III trial of denosumab versus zoledronic acid.

Martin M, Bell R, Bourgeois H, Brufsky A, Diel I, Eniu A, Fallowfield L, Fujiwara Y, Jassem J, Paterson AH, Ritchie D, Steger GG, Stopeck A, Vogel C, Fan M, Jiang Q, Chung K, Dansey R, Braun A.

Clin Cancer Res. 2012 Sep 1;18(17):4841-9. Epub 2012 Aug 14.

37.

A phase 2 trial of standard-dose cyclophosphamide, doxorubicin, vincristine, prednisone (CHOP) and rituximab plus bevacizumab for patients with newly diagnosed diffuse large B-cell non-Hodgkin lymphoma: SWOG 0515.

Stopeck AT, Unger JM, Rimsza LM, LeBlanc M, Farnsworth B, Iannone M, Glenn MJ, Fisher RI, Miller TP.

Blood. 2012 Aug 9;120(6):1210-7. doi: 10.1182/blood-2012-04-423079. Epub 2012 Jun 25.

38.

Task-based evaluation of segmentation algorithms for diffusion-weighted MRI without using a gold standard.

Jha AK, Kupinski MA, Rodríguez JJ, Stephen RM, Stopeck AT.

Phys Med Biol. 2012 Jul 7;57(13):4425-46. doi: 10.1088/0031-9155/57/13/4425. Epub 2012 Jun 20. Erratum in: Phys Med Biol. 2013 Jan 7;58(1):183.

39.

The role of targeted therapy and biomarkers in breast cancer treatment.

Stopeck AT, Brown-Glaberman U, Wong HY, Park BH, Barnato SE, Gradishar WJ, Hudis CA, Rugo HS.

Clin Exp Metastasis. 2012 Oct;29(7):807-19. doi: 10.1007/s10585-012-9496-y. Epub 2012 Jun 13. Review.

PMID:
22692561
40.

Prevalence of depression in adults with haemophilia.

Iannone M, Pennick L, Tom A, Cui H, Gilbert M, Weihs K, Stopeck AT.

Haemophilia. 2012 Nov;18(6):868-74. doi: 10.1111/j.1365-2516.2012.02863.x. Epub 2012 May 30.

PMID:
22642565
41.

Role of denosumab in the management of skeletal complications in patients with bone metastases from solid tumors.

Brown-Glaberman U, Stopeck AT.

Biologics. 2012;6:89-99. doi: 10.2147/BTT.S20677. Epub 2012 Apr 12.

42.

Cost-effectiveness of denosumab vs zoledronic acid for prevention of skeletal-related events in patients with solid tumors and bone metastases in the United States.

Stopeck A, Rader M, Henry D, Danese M, Halperin M, Cong Z, Qian Y, Dansey R, Chung K.

J Med Econ. 2012;15(4):712-23. doi: 10.3111/13696998.2012.675380. Epub 2012 Mar 27.

PMID:
22409231
43.

A phase II study of lapatinib and bevacizumab as treatment for HER2-overexpressing metastatic breast cancer.

Rugo HS, Chien AJ, Franco SX, Stopeck AT, Glencer A, Lahiri S, Arbushites MC, Scott J, Park JW, Hudis C, Nulsen B, Dickler MN.

Breast Cancer Res Treat. 2012 Jul;134(1):13-20. doi: 10.1007/s10549-011-1918-z. Epub 2011 Dec 24.

44.

Phase I safety and pharmacokinetic study of bavituximab, a chimeric phosphatidylserine-targeting monoclonal antibody, in patients with advanced solid tumors.

Gerber DE, Stopeck AT, Wong L, Rosen LS, Thorpe PE, Shan JS, Ibrahim NK.

Clin Cancer Res. 2011 Nov 1;17(21):6888-96. doi: 10.1158/1078-0432.CCR-11-1074. Epub 2011 Oct 11.

45.

Incidence, risk factors, and outcomes of osteonecrosis of the jaw: integrated analysis from three blinded active-controlled phase III trials in cancer patients with bone metastases.

Saad F, Brown JE, Van Poznak C, Ibrahim T, Stemmer SM, Stopeck AT, Diel IJ, Takahashi S, Shore N, Henry DH, Barrios CH, Facon T, Senecal F, Fizazi K, Zhou L, Daniels A, Carrière P, Dansey R.

Ann Oncol. 2012 May;23(5):1341-7. doi: 10.1093/annonc/mdr435. Epub 2011 Oct 10.

PMID:
21986094
46.

How do we define efficacy in comparing osteoclast-targeted agents in metastatic breast cancer?

Gralow JR, Lipton A, Stopeck AT.

J Clin Oncol. 2011 Sep 10;29(26):3591-2; author reply 3592-3. doi: 10.1200/JCO.2011.36.5759. Epub 2011 Aug 15. No abstract available.

PMID:
21844502
47.

HSP90 inhibition is effective in breast cancer: a phase II trial of tanespimycin (17-AAG) plus trastuzumab in patients with HER2-positive metastatic breast cancer progressing on trastuzumab.

Modi S, Stopeck A, Linden H, Solit D, Chandarlapaty S, Rosen N, D'Andrea G, Dickler M, Moynahan ME, Sugarman S, Ma W, Patil S, Norton L, Hannah AL, Hudis C.

Clin Cancer Res. 2011 Aug 1;17(15):5132-9. doi: 10.1158/1078-0432.CCR-11-0072. Epub 2011 May 10.

48.

Randomized, placebo-controlled, double-blind, phase II study of axitinib plus docetaxel versus docetaxel plus placebo in patients with metastatic breast cancer.

Rugo HS, Stopeck AT, Joy AA, Chan S, Verma S, Lluch A, Liau KF, Kim S, Bycott P, Rosbrook B, Bair AH, Soulieres D.

J Clin Oncol. 2011 Jun 20;29(18):2459-65. doi: 10.1200/JCO.2010.31.2975. Epub 2011 May 9.

PMID:
21555686
49.

Systemic treatment of early breast cancer--a biological perspective.

Greenberg S, Stopeck A, Rugo HS.

J Surg Oncol. 2011 May 1;103(6):619-26. doi: 10.1002/jso.21842. Review.

PMID:
21480257
50.

Evaluating segmentation algorithms for diffusion-weighted MR images: a task-based approach.

Jha AK, Kupinski MA, Rodríguez JJ, Stephen RM, Stopeck AT.

Proc SPIE Int Soc Opt Eng. 2010 Feb 27;7627. pii: 76270L (2010).

Supplemental Content

Loading ...
Support Center